Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dextromethorphan for symptom severity and brain function in obsessive-compulsive disorder (ERP study)
IRCT20130518013359N6Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dextromethorphan in obsessive compulsive disorder (OCD), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Change in obsessive-compulsive disorder symptom severity and Change in brain function measured by ERP. Started Feb 2022; status: completed.
02
Drugs
dextromethorphan
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on IRCT20130518013359N6.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20130518013359N6.